investors & media
NASDAQ: (common stock)
Data Provided by Refinitiv. Minimum 15 minutes delayed.
With 51 patients enrolled, data from the long-term follow-up study (LTF-303) show that all patients treated with beti-cel who achieve transfusion independence (TI) remain free from transfusions, with the longest follow-up of seven years Across Phase 3 studies, 89% (32/36) of evaluable patientsRead more
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 7, 2021-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Goldman Sachs 42 nd Annual Global Healthcare Conference, Tuesday, June 8 , at 8:50 a.m. ET .Read more
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 7, 2021-- bluebird bio, Inc . (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin for sickle cell disease (SCD) gene therapyRead more